KKKohei Kumegawa

Kohei Kumegawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kohei Kumegawa has a total of 183 co-authors. Here are the top co-authors by number of shared publications:

  • Reo Maruyama

    Division of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

    25 shared publications
  • Hiromu Suzuki

    Division of Molecular Biology, Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan

    11 shared publications
  • Liying Yang

    Division of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan

    10 shared publications
  • Masahiro Kai

    Division of Molecular Biology, Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan

    10 shared publications
  • Akihiro Tsuyada

    Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan

    9 shared publications
  • Takeshi Niinuma

    Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan

    9 shared publications

Latest Publications

  • Open Access

    Clonal lineage tracing and parallel multiomics profiling reveal transcriptional heterogeneity induced by ARID1A deficiency

    by Kenichi Miyata, Liying Yang, Yuxiao Yang, Kohei Kumegawa, Reo Maruyama

    Transcriptional heterogeneity drives malignant progression, yet how it emerges within tumors remains unclear. By combining genetic perturbation and lineage tracing with parallel single-cell multiomics, we tracked the consequences of ARID1A loss within individual clonal lineages. ARID1A deficiency increased transcriptional variability both within and across clones, recurrently giving rise to diverse transcriptional profiles that did not converge on a common, coordinated pattern. This variability was accompanied by broadened chromatin accessibility at normally silenced loci and depended on residual SMARCA4 activity. Clones in which this variability was prominent showed no growth advantage under standard conditions but were preferentially recovered under specific environmental stresses and during lung colonization, a context dependence consistent with bet-hedging. Our findings suggest that loss of an epigenetic regulator can promote tumor evolution by relaxing transcriptional constraints and widening the range of phenotypes accessible to a clonal lineage, rather than by imposing a single fixed phenotype.

  • Open Access

    Plasticity of extrachromosomal DNA segregation during drug adaptation

    by Chikako Shibata, Kenichi Miyata, Marwa Akao, Kohei Kumegawa, Yumiko Maruyama, Liying Yang, Mana Nagamoto, Ryu-Suke Nozawa, Toru Hirota, Shingo Iwami, et al.

    Uneven segregation during mitosis is a striking feature of extrachromosomal DNA (ecDNA). Because ecDNA lacks a centromere, it is thought to segregate stochastically, generating intratumoral heterogeneity in genomic copy number. Drug treatment can readily change ecDNA copy number, enabling cells to acquire drug resistance, yet whether these changes reflect static selection of pre-existing clones or active reconfiguration under stress remains unresolved. To address this, we develop a high-throughput framework combining single-cell DNA sequencing with cellular barcoding for clonal tracking. Single-cell cloning reveals that not all clones exhibit identical segregation modes even under drug-free conditions. Under treatment, resistant populations do not simply arise from pre-existing clones with favorable ecDNA states; instead, some clones actively reconfigure their segregation behavior to generate resistant cells. Thus, although ecDNA generally segregates stochastically, it can undergo nonrandom, actively regulated segregation under drug stress, raising the possibility of therapeutically targeting ecDNA segregation mechanisms to counteract adaptive resistance.

  • Open Access

    Colorectal cancer co-opts an epidermal wound healing program during metastasis to generate disseminated tumor cells

    by Mizuho Sakahara, Takuya Okamoto, Kohei Kumegawa, Yasuko Natsume, Daisuke Kusama, Hitomi Yamanaka, Rie Komatsuzaki, Katsuyuki Yaginuma, Upasna Srivastava, Atsushi Takahashi-Kanemitsu, et al.

    Metastasis is the principal cause of death from colorectal cancer (CRC), yet the cellular states that enable tumor dissemination remain poorly defined. Disseminated tumor cells (DTCs) are rare, transient, and clinically inaccessible, limiting mechanistic insight into their biology. Here we show that CRC cells transiently adopt a wound-healing program normally used by epidermal keratinocytes during tissue repair to enable metastatic dissemination. Using serial orthotopic transplantation of patient-derived organoids to model metastasis, we find that DTCs lose cancer stem cell features and instead express wound-inducible keratins, including KRT17, before metastatic outgrowth. This state is reversible, as cells reacquire primary tumor–like characteristics upon colonization of distant organs. Mechanistically, this transition is associated with reduced EZH2 activity and activation of YAP signaling. Clinically, KRT17⁺ cells localize to the invasive front of primary CRCs and are absent from adjacent normal tissue. These findings uncover unexpected lineage plasticity across distinct developmental origins and identify a transient, targetable state critical for metastatic progression.

  • Open Access

    Ribosome biogenesis as a potential therapeutic target in KRAS mutant colorectal cancer

    by Yui Tanaka, Mizuho Sakahara, Hitomi Yamanaka, Yasuko Natsume, Daisuke Kusama, Kohei Kumegawa, Harunori Yoshikawa, Yuich Abe, Koji Okabayashi, Shimpei Matui, et al.

    Molecular targeted therapies targeting KRAS signaling have significantly improved patient outcomes, but they have not achieved sufficient therapeutic efficacy in colorectal cancer (CRC). Here, we demonstrate that a subset of KRAS-mutant CRC cells transitions to a cellular state characterized by enhanced ribosome biogenesis upon KRAS signaling inhibition. The mitogen-activated protein kinase kinase inhibitor, trametinib, and AMG510 induce a cellular state characterized by a gene expression profile highly enriched for ribosome biogenesis. We find that they are vulnerable to the inhibition of RNA polymerase I, and they exhibit synergistic anti-tumor effects with trametinib in an autochthonous mouse model of intestinal tumors and human patient-derived organoids (PDOs). These observations demonstrate that high ribosome biogenesis induced by KRAS inhibition is indispensable to maintain this cellular state and is a potential therapeutic target. Overall, this study reveals novel mechanisms of drug tolerance to KRAS inhibition, thereby facilitating the development of new therapeutic strategies.


  • Open Access

    Transgelin defines pro-tumorigenic cancer-associated fibroblasts in pancreatic cancer

    by Xingxing Wang, Keiko Shinjo, Kohei Kumegawa, Reo Maruyama, Shinji Mii, Yukihiro Shiraki, Tastunori Nishimura, Yoshiteru Murofushi, Miho Suzuki, Takanobu Kabasawa, et al.

    Introduction Pancreatic ductal adenocarcinoma (PDAC) is characterised by a pronounced desmoplastic reaction, predominantly composed of cancer-associated fibroblasts (CAFs), including myofibroblastic CAFs (myCAFs). Methods We performed a single-cell assay for transposase-accessible chromatin with high-throughput sequencing (scATAC-seq) and single-cell RNA sequencing (scRNA-seq) on pancreas tissues from KPC mice (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) to characterise myCAF heterogeneity. A transgelin (Tagln) knockout orthotopic mouse model was used to determine the functional role of Tagln. Results Epigenetic profiling uncovered heterogeneity within the myCAF population, revealing distinct subclusters characterised by specific transcription factor (TF) motifs, such as Srf, Cebpb, Prrx1, and Smad4. We identified three transcriptionally distinct myCAF subtypes, each enriched for unique TF–associated signalling pathways. Among the identified myCAF subtypes, Tagln emerged as a potential functional driver. Tagln knockout mice exhibited significantly reduced PDAC tumour burden compared to wild-type. Analysis of TCGA revealed that high TAGLN expression in PDAC samples was associated with poor survival. Conclusions Our findings highlight the functional heterogeneity of myCAFs and identify TAGLN-expressing myCAFs as critical mediators of tumour progression, providing evidence that targeting stromal TAGLN may represent a promising therapeutic strategy for PDAC.


  • Open Access

    Characterizing heterogeneous cis-regulatory elements in gene regulatory programs associated with breast cancer

    by Chisa Hori, Kohei Kumegawa, Sumito Saeki, Yoko Takahashi, Liying Yang, Tomoyoshi Nakadai, Kazutaka Otsuji, Chikako Takahata, Yukinori Ozaki, Natsue Uehiro, et al.

    Cis-regulatory elements (CREs) control oncogene expression and malignant phenotypes. The high clinicopathological heterogeneity of cancer cannot be explain


  • Open Access

    Breast cancer identity is defined by specialized enhancer sets via lysine deacetylation

    by Hiroaki Tachiwana, Kohei Kumegawa, Ryota Matsudo, Ai Katsuma, Atsushi Okabe, Nao Yoshida, Xufeng Shu, Masaki Kato, Tamiko Minamisawa, Akihiro Ito, et al.

    Breast cancer subtypes are defined by distinct transcriptional programs, yet the epigenetic mechanisms underlying subtype-specific gene regulation remain unclear. Enhancers, key regulators of gene expression and cell identity, are well positioned to define breast cancer subtypes. Here, we identify a previously unrecognized class of enhancers, termed hypoacetylation-defined (HD) enhancers, that regulate cancer-related genes in a luminal breast cancer cell line. HD enhancers are defined by RNA polymerase II dissociation upon lysine deacetylase inhibition, and bidirectional eRNA transcription. They are distinct from super-enhancers, require a specific Mediator subunit for gene-specific transcription, and form extensive chromatin interactions suggestive of a hub-like architecture. Analyses of clinical datasets further identified a subset of HD enhancers, termed HD cluster 1 enhancers, which classify patients into breast cancer subtypes and are associated with expression quantitative trait loci linked to subtype-specific gene expression. This study identifies the lysine deacetylation-regulated cell identity enhancers, which are potential therapeutic targets.

  • Open Access

    DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma

    by Kazuya Ishiguro, Hiroshi Kitajima, Takeshi Niinuma, Reo Maruyama, Tomohide Tsukahara, Yoshihiko Hirohashi, Akari Takaya, Kohei Kumegawa, Ayano Yoshido, Shohei Sekiguchi, et al.


  • Open Access

    Clonal lineage tracing and parallel multiomics profiling reveal transcriptional diversification induced by ARID1A deficiency

    by Kenichi Miyata, Liying Yang, Yuxiao Yang, Kohei Kumegawa, Reo Maruyama

    Phenotypic heterogeneity among genetically identical cancer cells underpins tumor progression and therapy resistance. However, the mechanism of epigenetic dysregulation that drives such divergence remains unclear. This study introduces integrated multimodal experimental platform specialized in analyzing inter/intraclonal heterogeneity (IMPACH), a scalable platform that integrates lineage tracing, genetic perturbation, and multimodal single-cell analysis. Utilizing IMPACH, results revealed that loss of epigenetic regulators-particularly ARID1A-enhances transcriptomic and epigenetic heterogeneity under controlled conditions. ARID1A deficiency promotes stochastic chromatin opening and induces an atypical gene expression program associated with poor clinical outcomes. Despite increased epigenetic randomness, chromatin changes remain localized to regulatory elements, partially linked to SMARCA4 binding sites. These findings revealed that chromatin remodeling defects promote clonal diversification through both stochastic and constrained mechanisms. Thus, owing to its scalability and versatility, IMPACH provides a robust framework for elucidating how epigenetic perturbations shape cellular heterogeneity in cancer.